Validation of a 12-Gene Colon Cancer Recurrence Score ® in Stage II Colon Cancer Patients from CALGB 9581 A.P. Venook 1, D. Niedzwiecki 2, M. Lopatin 3,

Slides:

Advertisements

Similar presentations

NFPA Urban Fire Safety Project Urban Fire Forum October 21, 2011 Sharon Gamache Program Director High-Risk Outreach Programs.

Advertisements

PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors Scott Kopetz 1, Jayesh Desai 2, Emily Chan 3, J Randolph Hecht 4, Peter J O’Dwyer.

Oncotype DX® Breast Cancer Assay Clinical Data Review

The Present and Future of Genomics in DCIS

Implicaciones clínicas de los subtipos intrínsecos de cáncer de mama

Validation of a 12-gene colon cancer Recurrence Score in stage II colon cancer patients from CALGB 9581 A.P. Venook 1, D. Niedzwiecki 2, M. Lopatin 3,

Copyright 2014 Center to Advance Palliative Care. Reproduction by permission only. Palliative care is specialized care for people with serious illness.

Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

Laura J. Van ‘t Veer Helen Diller Family Comprehensive Cancer Center University of California, San Francisco Biology of disease Who is at risk for what.

Randomized Phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung.

Pilot Experience with Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer – NCCTG Intergroup N0147 J. Huang*, D. J. Sargent*,

Major Events for Segmented Audiences Margaret Miller Assistant Vice President for Alumni Affairs Princeton University.

Experimental Design and Biospecimens David F. Ransohoff, MD Division of Gastroenterology and Hepatology; Dept. of Medicine.

References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.

The 12-gene DCIS Score Assay and Quantitative Gene Expression for ER, PR, and HER2: Experience with 3,947 Patients Alvarado MD, 1 Tan V, 2 Bailey H, 2.

Biomarker-driven treatment decisions in stage II colon cancer - making sense of what we know June 7, 2010 Neal J. Meropol, M.D. Chief, Division of Hematology.

Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions 1 Do I need surgery? chemotherapy? radiation? INVASIVE BREAST.

There is more to clinical trials than chemotherapy and survival Alan P. Venook, M.D. University of California, SF.

Tang G et al. Proc SABCS 2010;Abstract S4-9.

Desirable Surveillance Network National Prion Disease Pathology Surveillance Center Locations Regularly Performing.

The University of North Carolina at Chapel Hill Fall Board of Visitors Meeting Friday, September 19, 2008 Development Update By Matthew G. Kupec Vice Chancellor.

Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.

Geography of the United States the-united-states-of-america ?op=1.

Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.

A Quantitative Multi-Gene RT-PCR Assay for Prediction of Recurrence in Stage II Colon Cancer (CC): Selection of the Genes in 4 Large Studies and Results.

Genomic Health, Inc. Yuko Soneoka, Ph.D., J.D. Senior Corporate Counsel, IP Director of Intellectual Property January 31, 2013.

Welcome! San Francisco Bay Area Chapter Launch Event.

Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer Trial Study Regimen No. of Patients Disease-Free Survival (%) Hazard Ratio P-Value Overall.

Predicting Safety and Efficacy of Treatment for Colon Cancer Clinical Science Symposium Towards Personalized Medicine: Trials and Technologies That Will.

Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,

Kelvin K. Tsai, M.D., Ph.D. Laboratory for Tumor Epigenetics and Stemness (TES Lab) NATIONAL INSTITUTE OF CANCER RESEARCH NATIONAL HEALTH RESEARCH INSTITUTES.

Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients (pts) treated on CALGB

Prognostic and predictive blood- based biomarkers in patients with advanced pancreatic cancer: Results from CALGB A.B. Nixon 1, H. Pang 1,2, M. Starr.

KRAS MUTATION, CANCER RECURRENCE AND PATIENT SURVIVAL IN STAGE III COLON CANCER: FINDINGS FROM CALGB S. Ogino, J.A. Meyerhardt, N. Irahara, D. Niedzwiecki,

A Tour of America's Best Hospitals It's no secret that all hospitals are not equal  The special quality shared by the 152 that made it into.

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.

Effect of 21-Gene Reverse- Transcriptase Polymerase Chain Reaction Assay on Treatment Recommendations in Patients with Lymph Node-Positive and Estrogen.

The presence of 18q loss of heterozygosity (LOH) predicts decreased disease-free and overall survival in stage II colon cancer: A study of CALGB Protocol.

Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.

Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer Mayer EL et al. Proc SABCS 2010;Abstract P

Individualizing Adjuvant Therapy on the Basis of Molecular Markers Charles S. Fuchs, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA.

Severity of Obesity and Six-Month Outcomes among Youth in Pediatric Weight Management: POWER Retrospective Cohort Study B Sweeney, MD 1 ; E King,

Use of Oncotype Dx® Testing Breast SSG meeting 10 th July 2015 Dr Rebecca Bowen.

Prostate Cancer Management: A Guide for Patients and Caregivers

Integrating legal services into antenatal and postnatal care for HIV positive and HIV negative women in South Africa S. Maman 1, D. Holness 2, D. Moodley.

The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.

Meta-Analysis of the Decision Impact of the 21-Gene Breast Cancer Recurrence Score in Clinical Practice Hornberger J, Chien R. Proc SABCS 2010;Abstract.

Scott Kopetz, MD, PhD Department of Gastrointestinal Medical Oncology

Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.

Trauma and Child Brain Development: the physiological impact of traumatic stress and implications service systems Joshua Arvidson, MSS., LCSW Alaska Child.

Celia Cervantes November 4, 2012 Neonatal Nurse and Pediatrician.

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

G Mustacchi 1, F Zanconati 2, D Bonifacio 2, L Morandi 3, MP Sormani 4, A. Gennari 5, P Bruzzi 4 1: Centro Oncolgico University of Trieste 2: Inst of Pathology,

Building Improvement Capability in Communities Hub

Immunoscore Prognostic in Colon Cancer

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.

Figure 3 Semantic model of the active surveillance (AS) timeline

Advancing PrEP in family planning clinics: what will it take?

New CHEST Editorial Board Members

Use of SAS® Graph Template Language and HIGHLOWPLOT to Create a Next-Generation Sequencing Multi-Gene Panel Grid John Bennett Statistical Programmer Genomic.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Comparison of molecular and pathologic features of stage II and stage III colon cancer in 4 large studies conducted for development of the 12-gene colon.

Single Sample Expression-Anchored Mechanisms Predict Survival in Head and Neck Cancer Yang et al Presented by Yves A. Lussier MD PhD The University.

Fall 2018, COMP 562 Poster Session

Title Author Names UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC Add map, add med rec pic, flow diagram of.

NOAH: pCR Results Patients (%) P=0.002 P=0.003 P=0.29 P=0.43 With T

From Innovation to Commercialization Access to Data

OncotypeDX DCIS test use and clinical utility: A SEER population-based study Yao Yuan, PhD, MPH, Alison Van Dyke, MD, PhD, Serban Negoita, MD, DrPH & Valentina.

Pre- and post-vorinostat values of ER-related gene expression using the Oncotype DX 21-gene assay. Pre- and post-vorinostat values of ER-related gene expression.

Presentation transcript:

Validation of a 12-Gene Colon Cancer Recurrence Score ® in Stage II Colon Cancer Patients from CALGB 9581 A.P. Venook 1, D. Niedzwiecki 2, M. Lopatin 3, M. Lee 3, P. N. Friedman 4, W. Frankel 5, K. Clark-Langone 3, C. Yoshizawa 3, C. Millward 3, S. Shak 3, R. M. Goldberg 6, N. N. Mahmoud 7, R. L. Schilsky 4, M. M. Bertagnolli 8 1. University of California, San Francisco, San Francisco, CA; 2. Duke University, Durham, NC; 3. Genomic Health, Redwood City, CA; 4. The University of Chicago, Chicago, IL; 5. The Ohio State University, Columbus, OH; 6. University of North Carolina at Chapel Hill, Chapel Hill, NC; 7. University of Pennsylvania, Philadelphia, PA; 8. Brigham and Women's Hospital, Boston, MA Venook AP, et al. ASCO Abstract 3518 (poster presentation).

2 CALGB 9581: A Unique Opportunity to Test the Oncotype DX ® Assay in Low/Standard Risk Stage II Colon Cancer Sampling design with 690 evaluable patients, including 162 recurrence events, representative of 1,672 stage II colon cancer patients from CALGB 9581Sampling design with 690 evaluable patients, including 162 recurrence events, representative of 1,672 stage II colon cancer patients from CALGB 9581 A population where risk discrimination is challenging with conventional clinical and pathologic factorsA population where risk discrimination is challenging with conventional clinical and pathologic factors Venook AP, et al. ASCO Abstract 3518 (poster presentation).

3 CALGB 9581: Second Successful Prospectively-Designed Confirmation Study Venook AP, et al. ASCO Abstract 3518 (poster presentation). RS, Recurrence Score ®

4 CALGB 9581: Improving the Ability to Discriminate High vs. Low Risk of Recurrence in Standard Risk Stage II Colon Cancer Venook AP, et al. ASCO Abstract 3518 (poster presentation). RS, Recurrence Score ®